Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oral rehydration solution

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Oral rehydration solution. Displaying page 1 of 1.
    EudraCT Number: 2015-002004-92 Sponsor Protocol Number: OralRehyd Start Date*: 2015-09-09
    Sponsor Name:Medizinische Universität Graz, Klinische Abteilung für allgemeine Pädiatrie
    Full Title: Acute gastroenteritis in paediatrics : Comparison of two oral rehydration preparations - A randomized pilot study
    Medical condition: acute gastroenteritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10017784 Gastric flu LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019787-36 Sponsor Protocol Number: FARM8E53XM Start Date*: 2011-07-04
    Sponsor Name:ISTITUTO PER L`INFANZIA BURLO GAROFOLO
    Full Title: ORAL ONDANSETRON VS DOMPERIDONE FOR SYMPTOMATIC TREATMENT OF VOMITING DURING ACUTE GASTROENTERITIS IN CHILDREN: MULTICENTRE RANDOMIZED CONTROLLED TRIAL
    Medical condition: Acute gastroenteritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066762 LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005700-15 Sponsor Protocol Number: marha1983 Start Date*: 2013-01-07
    Sponsor Name:Lennart Svensson Linköping University Medical Faculty
    Full Title: Can 5-HT3 receptor antagonists be used to limit vomiting in rota- and norovirus infections?
    Medical condition: Virus caused vomiting and effect of the antiemetic drug Ondansetron
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001651-31 Sponsor Protocol Number: 1.0 Start Date*: 2017-11-30
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: EMPOWER: EMesis in Pregnancy - Ondansetron With mEtoclopRamide.
    Medical condition: Nausea and Vomiting in pregnancy Hyperemesis gravidarum
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004797-18 Sponsor Protocol Number: Start Date*: 2017-06-26
    Sponsor Name:Imperial College London
    Full Title: Pilot study of the GLP-1 agonist, Liraglutide, on decreasing parenteral support requirements in short bowel patients.
    Medical condition: Intestinal failure with an underlying aetiology of short bowel
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-000256-28 Sponsor Protocol Number: LAP117314 Start Date*: 2014-08-21
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for t...
    Medical condition: Diarrhoea associated with treatment with lapatinib and capecitabine for metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) GB (Completed) IT (Completed) GR (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 13:02:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA